Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOYAGER
2025-521420-30-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adalimumab and risankizumab in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (2 arms), sponsored by University Medical Center Groningen. Planned start Jan 2026; status: authorised.
02
Drugs
adalimumabrisankizumab
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2025-521420-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521420-30-00.